CENTRADOL Transdermal Patch
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
21-03-2023
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
BUPRENORPHINE
Available from:
Grunenthal GmbH
Pharmaceutical form:
Transdermal Patch
Authorization date:
2002-05-03
Summary of Product characteristics
License
IRISH MEDICINES BOARD ACTS 1995 AND 2006
MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007
(S.I. No.540 of 2007)
PA1032/002/001
Case No: 2065739
The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to
Grunenthal GmbH
Zieglerstr. 6, D-52078 Aachen, Germany
an authorisation, subject to the provisions of the said Regulations, in respect of the product
Centradol 35 micrograms/h Transdermal Patch
The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as
may be specified in the said Regulations as listed on the reverse of this document.
This authorisation, unless previously revoked, shall continue in force from 21/05/2009.
Signed on behalf of the Irish Medicines Board this
________________
A person authorised in that behalf by the said Board.
Irish Medicines Board
______________________________________________________________________________________________________________________
Date Printed 21/05/2009
CRN 2065739
page number: 1
Part II
Summary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT
Centradol 35 micrograms/h Transdermal Patch
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
One transdermal patch contains
Read the complete document
